🌍 ObsEva SA (company was delisted NASDAQ) (OBSV) - Form 6-K Filing
Filing Date: 2022-06-28
Accepted: 2022-06-28 16:13:56
Event Type: Regulatory Update
Event Details:
53 LR of the SIX Swiss Exchange GENEVA, Switzerland June 28, 2022 ObsEva SA (NASDAQ OBSV SIX OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Yselty (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age. Yselty offers a potentially best-in-class efficacy rate 1,2,3 and favorable tol.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
✅ Licensing Agreement
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Investor Contact: Katja Buhrer katja.buhrer@obseva.com +1 (917) 969-3438 1. Stewart E, ASRM 2020;
🌍 ObsEva SA (company was delisted NASDAQ) (OBSV) - Form 6-K Filing
Filing Date: 2022-06-28
Accepted: 2022-06-28 16:13:56
Event Type: Regulatory Update
Event Details:
💼 Business Developments:
📞 Contact Information: